AEON Biopharma Inc
AEON.WS
AEON.WS was delisted on the 26th of April, 2024.
53 hedge funds and large institutions have $5.62M invested in AEON Biopharma Inc in 2022 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 7 closing their positions.
0% more funds holding
Funds holding: 53 → 53 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
1% less capital invested
Capital invested by funds: $5.67M → $5.62M (-$47.3K)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
+$10.8K |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$4.67K |
| 3 |
HIM
HGC Investment Management
Toronto,
Ontario, Canada
|
+$3.37K |
| 4 |
CIM
Cowen Investment Management
New York
|
+$1.01K |
| 5 |
CS
Clear Street
New York
|
+$636 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Parallax Volatility Advisers
San Francisco,
California
|
-$11.5K |
| 2 |
Verition Fund Management
Greenwich,
Connecticut
|
-$7K |
| 3 |
MF
Magnetar Financial
Evanston,
Illinois
|
-$5K |
| 4 |
AGM
Alpine Global Management
New York
|
-$3K |
| 5 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$3K |
AEON.WS Hedge Fund Activity: Q4 2022 in Review
53 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma Inc (AEON.WS) for Q4 2022, worth a combined $5.62M — down 0.83% from $5.67M a quarter earlier.
Fund positioning in AEON.WS was balanced in Q4 2022: 7 funds opened new positions, 7 closed out, 4 added to existing stakes and 6 trimmed.
The largest buyer was Cowen and Company, opening a new position worth an estimated $10.8K. The largest seller was Parallax Volatility Advisers, cutting an estimated $11.5K.
- 53 institutional investors held AEON Biopharma Inc (AEON.WS) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $5.62M of AEON Biopharma Inc stock for Q4 2022, down 0.83% quarter-over-quarter.
- 7 funds opened new AEON Biopharma Inc positions in Q4 2022 and 7 closed out, a net change of 0 holders.
- The largest AEON Biopharma Inc buyer in Q4 2022 was Cowen and Company, an estimated $10.8K added.
- The largest AEON Biopharma Inc seller in Q4 2022 was Parallax Volatility Advisers, an estimated $11.5K sold.
Based on aggregated 13F filings for Q4 2022.